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ABSTRACT:  
 
Introduction: Tight glycemic control (TGC) remains controversial, and successful, 
consistent and effective protocols elusive. This research analyses data from 2 TGC 
trials for root causes of the differences achieved in control and thus potentially in 
glycemic and other outcomes. The goal is to uncover aspects of successful TGC and 
delineate the impact of differences in cohorts.   
 
Methods: A retrospective analysis using records from a 211 patient subset of the 
Glucontrol trial taken in Liege, Belgium and 393 patients from SPRINT in New 
Zealand. SPRINT targeted 4.0-6.0 mmol/L similar to the Glucontrol-A (N = 142) 
target of 4.4-6.1 mmol/L. The Glucontrol-B (N = 69) target was 7.8-10.0 mmol/L. 
Cohorts were matched by APACHE II score and percentage males (p > 0.35), 
however the Glucontrol cohort was slightly older (p = 0.011). Overall cohort and per-
patient comparisons (median [IQR]) are shown for: a) glycemic levels achieved; b) 
nutrition from carbohydrate (all sources); c) insulin dosing for this analysis. Intra- and 
Inter- patient variability are examined using clinically validated model-based insulin 
sensitivity metric and its hour-to-hour variation 
 
Results: Cohort blood glucose was: SPRINT: 5.7 [5.0 – 6.6], Glucontrol-A: 6.3 [5.3 – 
7.6], Glucontrol-B: 8.2 [6.9 – 9.4] mmol/L. Insulin dosing was: 3.0 [1.0 – 3.0], 1.5 
[0.5 – 3] and 0.7 [0.0 – 1.7] U/hr, respectively. Nutrition from carbohydrate (all 
sources) was: 435.5 [259.2 – 539.1], 311.0 [0.0 – 933.1], and 622.1 [103.7 – 1036.8] 
kcal/day, respectively.  
 
Median per-patient results for blood glucose are: 5.8 [5.3 – 6.4], 6.4 [5.9 – 6.9], and 
8.3 [7.6 – 8.8] mmol/L. For insulin dose: 3.0 [2.0 – 3.0], 1.5 [0.8 – 2.0], and 0.5 [0.0 – 
1.0] U/hr. For carbohydrate administration: 383.6 [207.4 – 497.7], 103.7 [0.0 – 
829.4], and 207.4 [0.0 – 725.8] kcal/day. Overall, SPRINT gave ~2x more insulin 
with a 3-4x narrower, but generally non-zero, range of nutritional input to achieve 
equally tight TGC with less hypoglycemia.  
 
SPRINT had much less hypoglycemia (<2.2 mmol/L) with 2% of patients, compared 
to Glucontrol-A (7.7%) and Glucontrol-B (2.9%), indicating much lower variability, 
with similar results for glucose levels <3.0 mmol/L. SPRINT also had less 
hyperglycemia (> 8.0 mmol/L) than Groups A and B.   
 
Glucontrol patients (A+B) had a ~2x wider range of insulin sensitivity than SPRINT. 
Hour-to-hour variation was similar. Hence, Glucontrol had greater inter-patient 
variability, but similar intra-patient variability. 
 
Conclusions: Protocols that dose insulin blind to carbohydrate administration can 
suffer greater outcome glycemic variability, even if average cohort glycemic targets 
are met. While the cohorts varied significantly in model-assessed insulin resistance, 
their variability was similar. Such significant intra- and inter- patient variability is a 
further significant cause and marker of glycemic variability in TGC. The results 
strongly recommended that TGC protocols be explicitly designed to account for 
significant intra- and inter- patient variability in insulin resistance, as well as 
specifying or having knowledge of carbohydrate administration to minimise 
variability in glycemic outcomes across diverse cohorts and/or centres. 
1.0 Introduction 
 
Critically ill patients often experience stress-induced hyperglycemia and high levels 
of insulin resistance [1-7]. Hyperglycemia worsens outcomes, increasing the risk of 
severe infection [8], myocardial infarction [1], and critical illness such as 
polyneuropathy and multiple organ failure [7]. The occurrence of hyperglycemia, 
particularly severe hyperglycemia, is associated with increased morbidity and 
mortality in this group of patients [1, 3]. Glycemic variability, and thus poor control, 
are also independently associated with increased mortality [9, 10]. 
 
Some studies have shown that tight glucose control (TGC) reduced intensive care unit 
patient mortality up to 45% with glycemic targets from 6.1 to 7.75 mmol/L [7, 11-13]. 
However, there is a little agreement on what constitutes desirable glycemic 
performance [14-16], particularly with regard to how TGC affects outcome. Despite 
the potential, many intensive care units do not used fixed protocols [4, 14, 15, 17, 18].  
 
In general, any glycemic control protocol must reduce elevated blood glucose levels 
with minimal hypoglycaemia, while accounting for inter-patient variability, 
conflicting drug therapies and dynamically evolving physiological condition. As 
patient condition evolves, particularly acutely, TGC and intensive insulin therapy can 
prove difficult. Protocols or clinical practises that utilize large insulin doses can thus 
suffer from high glycemic variability and excessive hypoglycemia [19]. As a result, 
several clinical trials have not achieved any benefit from TGC [19-22]. 
 
However, for comparison, any TGC result has to be viewed in the context of the 
following clinical aspects: 
 
• Patient condition and cohort (diagnostic codes, age, sex, etc). 
 
• Insulin dosing and carbohydrate administration from all sources, relative to 
the resulting blood glucose. 
 
• Intra-patient variability and adaptability of the protocol to acute changes in 
patient condition and resulting acute changes in metabolic response.  
 
• Inter-patient variability and/or adaptability of a protocol across patients with 
very different condition and thus different levels of insulin resistance. 
 
Thus, how TGC protocols are designed and implemented with respect to these clinical 
aspects will affect results.  
 
In particular, only 2 reported protocols explicitly considered carbohydrate intake in 
protocol design or implementation [13, 23-25]. Of these, only SPRINT was 
implemented long enough to show an impact on mortality. Importantly, carbohydrate 
input has been shown to be an independent marker of mortality in ICU patients [26], 
and thus worthy of consideration in designing overall metabolic management. 
 
More specifically, both cohorts and clinical practice varies between hospitals and 
countries. These differences may be physiological, part of different clinical practice 
standard or culture, or have other causes. In particular, nutritional standards and 
practice can vary substantially across countries and practices [26-28], and were thus 
potentially one cause of the high variability in nutritional intake and resulting 
glycemic outcome (the insulin protocols being equivalent) seen in the recent, initial 
NICE-SUGAR results [20], as well as in other results that have not yielded a 
mortality outcome [22]. Hence, to design protocols that will consistently yield any 
potential benefit of TGC these differences need to be assessed and/or quantified. 
 
This paper examines data from SPRINT [13] and a subset of the patients from one 
centre (CHU Liege, Belgium) of the Glucontrol [29] study. The analysis examines: 
 
• Association between carbohydrate administration, insulin dosing and 
glycemic outcome with respect to benefit (tight control) and risk 
(hypoglycemia). 
 
• Differences between cohorts in terms of insulin resistance, using a model-
based measure, and thus differences in inter-patient variability that might 
affect results. 
 
• Differences in the evolution of patient insulin resistance or insulin sensitivity 
between cohorts, and thus differences in intra-patient variability that also 
might affect results. 
 
In particular, while SPRINT was successful in achieving tight control, and reducing 
both hypoglycemia and mortality, the overall 7-country and 21-centre Glucontrol 
study was stopped early for reasons of compliance [29]. Thus, this evaluation will 
compare these results to determine if the differences in control and glycemic 
outcomes were due to differences in the patient cohorts or their evolution, or if they 
were due to aspects of the control protocol itself and/or its implementation in the 
context of the single Glucontrol centre studied. The results should provide insight and 
clearer guidance into the design and implementation of clinical TGC protocols. 
 
 
 
 
 
2.0 Methods 
 
2.1 SPRINT Protocol: 
 
SPRINT is a model-derived [24, 30, 31] protocol that controls both insulin and 
(carbohydrate) nutrition inputs. It was implemented at the Christchurch Hospital 
Department of Intensive Care on August 2005 [13] and has now been used on over 
1,000 patients. Interventions consider current and previous blood glucose 
measurements, current nutrition feed rate relative to a patient specific goal feed rate, 
and the prior hourly insulin dose to determine a new nutrition and insulin intervention 
for the coming 1-2 hour measurement interval defined in the protocol [13].  
 
More specifically, SPRINT titrates its insulin and nutrition inputs to achieve a target 
range of 4-6 mmol/L based on the patient’s current insulin sensitivity, determined in 
response to the insulin and nutrition interventions. More resistant patients receive 
more insulin and less nutrition (relative to their 100% goal feed rate). Stability and 
stopping criteria were also based on patient-specific insulin sensitivity. Hence, the 
protocol explicitly considers glycemic response in the context of both insulin and 
carbohydrate intake and is thus not blind to carbohydrate intake, which is unique, to 
the best of the authors’ knowledge. Virtually all other studies leave nutritional intake 
to local clinical standards and are thus “blind” to this critical parameter. 
A low carbohydrate enteral nutrition formula was also specified for all SPRINT 
patients per protocol, reducing the percentage of carbohydrate calories as a percentage 
of the total (specified) caloric intake. Minimum and maximum nutrition rates are 7.5 
and 25 kcal/kg/day respectively, with 2.7 to 9 kcal/kg/day (35-40%) from 
carbohydrates, which matches ACCP guidelines at the maximum level [27]. 
 
A further difference is that SPRINT uses insulin boluses, limited to 6U per hour to 
minimise insulin saturation [32-35]. Boluses also avoid high rates of insulin infusion 
being left running when clinical staff are occupied, increasing potential safety, which 
is an important aspect in situations where high insulin infusion rates combined with 
infrequent measurement can lead to significantly increased hypoglycemic events and 
variability resulting from acute changes in patient condition and metabolic response.  
 
2.2 Glucontrol: 
 
In the Glucontrol trial [29], patients were randomised in each centre to intensive 
(Group A, target: 4.4-6.1 mmol/L) and conventional (Group B, target: 7.8-10 
mmol/L) insulin therapy. Insulin was administered as a continuous IV infusion. 
Hourly measurement was used when the glycemic level was not within the target 
range. Otherwise, 2-hourly measurement was used in the case of limited variation of 
glycemia, defined as less than a 50% change from the previous glycaemia in 2-hour 
range. Finally, 4-hourly measurement was used when the glycemic level was less than 
50% of the highest glycemia of the four last hours. The insulin infusion rates are 
defined as shown in Tables 1-2 for the Intensive (Table 1) and Conventional (Table 2) 
protocols. Nutritional input was left to local and/or clinician standards, and was not 
explicitly considered in the design or implementation of the protocol. 
Table 1: Glucontrol protocol for intensive insulin therapy (Group A). (a) Starting 
insulin infusion rate. (b) Maintenance insulin infusion rates and increments.  
 
(a)    
Glycemia Insulin infusion rate 
< 110 mg/dl On hold 
110 - 140 mg/dl 1 U/H 
 140 - 180 mg/dl 2 U/H 
> 180 mg/dl 4 U/H 
(b)     
Glycemia Incremental insulin infusion rate 
> 300 mg/dl + 3 U/H 
180 - 300 mg/dl + 2 U/H 
140 - 180 mg/dl + 1 U/H 
110 - 140 mg/dl + 0.5 U/H 
 80 - 110 mg/dl + 0 U/H (target range) 
40 - 80 mg/dl Stop insulin, 
Hourly control of glycemia until > 80mg/dl 
< 40 mg/dl Stop insulin, 10gr glucose IVD, 
Call immediately physician, 
Hourly control of glycemia until > 80 mg/dl 
 
Table 2: Details of the Glucontrol protocol for conventional insulin therapy group 
(Group B). (a) Starting insulin infusion rate. (b) Maintenance insulin infusion rates 
and increments. 
  
(a) 
Glycemia Insulin infusion rate 
< 180 mg/dl On hold 
180 - 250 mg/dl 1 UI/H 
 250 - 300 mg/dl 2 UI/H 
> 300 mg/dl 4 UI/H 
(b) 
Glycemia Incremental insulin infusion rate 
> 300 mg/dl + 3 UI/H 
250 - 300 mg/dl + 2 UI/H 
180 - 250 mg/dl + 1 UI/H 
140 - 180 mg/dl + 0 UI/H (target range) 
 80 - 140 mg/dl Decrease 50% rate insulin 
40 - 80 mg/dl Stop insulin, 
Hourly control of glycemia until > 80mg/dl 
< 40 mg/dl Stop insulin, 10gr glucose IVD, 
Call immediately physician, 
Hourly control of glycemia until > 80 mg/dl 
 
2.3 Patient Data: 
 
In this study, data was used from 350 patients treated using the Glucontrol protocol at 
CHU de Liege, Belgium, between March 2004 and April 2005. Thus, the Glucontrol 
data is from only one centre out of the full study [29]. However, the other 21 centres 
were reported to be generally similar in behaviour. Hence, individual centres did not 
fail, but the overall trial did not achieve a clinical mortality outcome.   Figure 1 shows 
the selection of patients used in this analysis. Patients were eliminated from the 
analysis if they received no insulin for their entire stay (per protocol), had less than 5 
BG measurements over their time in the study or received little or no (recorded) 
carbohydrate administration (in any form) for more than 48 hours of their stay. All 
393 SPRINT patients study met these criteria. 
 
Figure 1: Cohort selection for SPRINT and Glucontrol A (Intensive) and B 
(Conventional) insulin therapy groups, resulting in 211 total Glucontrol patients being 
retained from the original 350. 
 
2.4 Glucose-Insulin System Model: 
 
The analysis of patient-specific insulin sensitivity uses a glucose insulin system model 
clinically validated in several studies [30, 31, 33, 36-42], defined:  
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In this model, G(t) is the total plasma glucose, I(t) is the plasma insulin, and Q(t) is 
the effect of previously infused insulin being utilized over time. EGPmax is the 
theoretical maximum endogenous glucose production (EGP) for a patient, which is 
suppressed with increasing glucose concentrations. This suppression, independent of 
non-insulin mediated glucose uptake by the central nervous system (CNS) is captured 
by the term with pG. In contrast, patient-specific insulin mediated glucose removal is 
captured with, SI, insulin sensitivity, which is identified from clinical data as a time 
varying value that reflects evolving patient condition [37-39]. Exogenous inputs are 
from the carbohydrate content of nutrition infusions that appear (P(t)) in plasma blood 
glucose via a two compartment model leading to P(t) [30, 36], and intravenous insulin 
administration uex(t). The remaining parameters are physiologically defined 
population constants for transport rates (n, k), saturation parameters (αG, αI), or 
volumes (VG, VI) that have been validated over several studies. 
 
The essential parameter that drives the observed patient-specific glycemic response to 
insulin and nutrition inputs is insulin sensitivity, SI. With this model, patient specific 
profiles can be generated for time-varying SI and its hour-to-hour variation as patient 
condition evolves. This task is achieved by fitting the model to retrospective clinical 
data for blood glucose measurements, and insulin and carbohydrate administration 
input data from the protocols [39]. The resulting insulin sensitivity profile has been 
validated in correlation to gold standard euglycemic clamp and IVGTT data [43-45], 
as well as in in-silico virtual trials [24, 31, 37, 38, 42]. 
 
 
2.5 Stochastic Model:  
 
Insulin sensitivity can evolve both gradually and acutely over time in ICU patients 
[36-38]. Stochastic models based on the hour-to-hour variation of this model variable 
yield distributions of the potential change in insulin sensitivity over 1-4 hours. These 
distributions then allow the creation of outcome blood glucose confidence bands for a 
given insulin and nutrition intervention (using the model). Thus, these models also 
quantify the potential affect on glycemic control of both minor (frequent) and acute 
(rare) evolutions in patient condition, as a function of current metabolic state and the 
clinical interventions. As a result, a model-based or adaptive TGC system can 
optimise interventions to minimise the risk of unexpected glycemic excursion and 
provide better decision making [37, 38, 42].  
 Knowledge of these dynamic changes provides further metrics of how metabolically 
dynamic and insulin resistant a given cohort may be. Therefore, they are another 
means of comparing cohorts for similarities or differences relevant to the quality of 
glycemic control achieved. While details are left to the references, a more dynamic 
and/or insulin resistant cohort would expect to have different bounds on this 
variability, and thus, all else equal, more variable glycemic control. Similarly, a more 
insulin resistant cohort would be expected to require more insulin to achieve equal 
glycemic outcomes. Thus, this model-based parameter and its variation can be used to 
quantify inter-patient and intra-patient variability for different cohorts, also enabling 
comparison of metabolic variability (over time and across patients) between cohorts.  
 
3.0 Results 
 
Table 3 compares the SPRINT and Glucontrol patients, where the latter are separated 
by TGC therapy (Groups A and B). Severity of illness over all Glucontrol (A+B) 
patients (via APACHE II) and percentage of male patients were similar (p > 0.35). 
The total Glucontrol cohort (A + B) was slightly older (p = 0.011).  
 
Median blood glucose for Groups A and B were 6.3 and 8.2 mmol/L respectively, as 
expected, and SPRINT was 5.7 mmol/L, which is similar to the Group A value due to 
their similar glycemic targets. However, variability is much different across these 
protocols. Median inter-quartile range (IQR) spread (75th – 25th percentile) was 1.6 
mmol/L for SPRINT, but 2.3 mmol/L for Group A and 2.5 mmol/L for Group B over 
the entire cohort(s).  
 
To achieve these results, SPRINT used approximately 2x as much insulin (median: 
2.8 U/hour) as Group A (median: 1.5 U/hour), which had a similar glycemic target, 
and 4x more than Group B (0.7 U/hour) with the higher glycemic target. It is 
important to recall that this analysis does not include patients from Glucontrol who 
did not receive insulin so the comparison is per protocol patient treated with insulin. 
Median nutrition, reported as appearance rate of carbohydrate in the nutritional 
formulas used, were broadly similar with median rates of 0.3, 0.6 and 0.42 mmol/min 
for Group A, Group B and SPRINT, respectively. However, it is also clear in Table 3 
that the spread of carbohydrate administration rates is much more tightly controlled 
by SPRINT with an IQR range of 0.27 mmol/min for SPRINT versus 0.9 mmol/min 
for Glucontrol Groups A and B.  
 With respect to variability and safety from hypoglycemia, SPRINT had increasingly 
less percentage of measurements below 4.0, 3.0 and 2.2 mmol/L compared to the 
similarly targeted Group A. Surprisingly, it also had less percentage of measurements 
below 3.0 and 2.2 mmol/L than Group B which had a much higher glycemic target 
indicating that this protocol had significant variability in glycemic response. As a 
percentage of patients, SPRINT thus had a much lower rate of hypoglycemia below 
2.2 mmol/L with 2% compared to Group A with 7.7% and the higher targeted Group 
B with 2.9%. The results for hyperglycemic measurements (percentage > 8.0 mmol/L) 
follow similar trends with expected differences for the higher targeted Group B. 
 
On a per-patient basis, the median patient’s median glucose was 6.4 mmol/L for 
Group A, 8.3 mmol/L for Group B, and 5.8 mmol/L for SPRINT, similar to those 
results for each overall cohort. However, the spread of median glucose levels across 
patients in each cohort was comparable for SPRINT with 1.1 mmol/L separating the 
25th and 75th percentile patient’s median blood glucose value, and Glucontrol with 1.0 
and 1.2 mmol/L spreads for Groups A and B, respectively.  
 
All of these results indicate that SPRINT maintained far tighter control on a cohort 
wide basis, but was comparable for intra-patient glycemic variability when analysing 
on a per-patient basis. Figure 2 provides cumulative distribution functions (CDFs) for 
each protocol’s entire cohort, where the steeper SPRINT CDF clearly shows the lower 
variability compared to Glucontrol. The Glucontrol CDFs are similar in slope, but 
shifted, indicating similar behaviour around each glycemic target for each cohort. The 
crossover of the Group A and SPRINT CDFs (at ~0.1 y-axis likelihood value) shows 
the higher hypoglycemia risk in the similarly targeted Group A cohort. 
 
Figure 3, shows the same cohort CDFs for insulin delivered and Figure 4 for 
nutritional carbohydrate (all sources) delivery rate. It is clear in Figures 3-4 that 
SPRINT provides insulin and nutrition far more consistently across the cohort 
(steeper and less zero valued CDFs). Thus, SPRINT provided a more constant 
nutrition rate in terms of carbohydrate appearance from all sources to balance the 
insulin given with far less variation in glycemic outcome. Importantly, nutrition rate 
was not a controlled variable and specified only to local standards in the Glucontrol 
study, which likely resulted in the greater variability in this input, even in the single 
center studied here, and thus the greater resulting glycemic variability.   
 
Figures 5 and 6 show empirical per-patient CDFs of model-based insulin sensitivity, 
SI, for each protocol. The shaded areas show the 90% confidence interval (90%CI) 
range and IQR, with the median patient noted by a line. It is clear that the Glucontrol 
cohort has higher insulin sensitivity at all likelihoods (y-axis) and for all observed 
percentile patients compared to the SPRINT cohort. It is also clear that the spread or 
range of insulin sensitivity across the cohort is ~2x wider for Glucontrol indicating a 
cohort with far greater inter-patient variability in insulin sensitivity / resistance, and 
thus one potential reason for its greater outcome glycemic variability. 
 
Figure 7 shows the distribution and hour-to-hour variation of fitted SI over time for all 
Glucontrol protocol patients where measurements were 1-2 hours apart enabling the 
use of the stochastic model of Lin et al [37, 38]. The x-axis shows the SI value at hour 
‘t’ and a vertical line shows the distribution of possible SI values in the next hour, t+1 
based on the entire cohort’s data. The median, IQR and 90% confidence interval lines 
provide context and indicate the potential variability and the shape of its distribution 
over the next hour. This plot thus shows the hour to hour distribution and likelihood 
of metabolic intra-patient glycemic variability in response to an insulin dose for the 
Glucontrol cohorts. Hence, it might be hypothesized that the greater the intra-patient 
variability in response to insulin interventions, the greater the resulting glycemic 
variability in response. 
 
Figure 8 provides the same data for SPRINT on a different y-axis scale for clarity. 
Figure 9 shows the combination of IQR, median and 90% CI from Figures 7-8 for 
both protocols. Figure 9 clearly shows very similar trends of median, IQR and 90% 
CI, indicating very similar metabolic intra-patient variability as assessed by this 
clinically validated parameter. Thus, despite the different inter-patient variation 
between SPRINT and Glucontrol in Figures 5-6, the hour to hour intra-patient 
variation between cohorts is very similar.   
 
Figure 10 summarises the control and metabolic balance delivered by the protocols 
between carbohydrate administration, insulin administration and resulting glucose 
levels. It uses three dimensional plots of median blood glucose, median insulin dose, 
and median carbohydrate administration rates for every patient in all 3 cohorts. For 
clarity, Figures 11-13 show the decomposition of this 3D plot into two of the 
dimensions for each parameter. It is clear in all three of Figures 11-13 that the 
SPRINT data and glycemic outcomes are far less variable and/or more tightly 
controlled. This result is particularly valid with respect to the median nutrition rate 
and carbohydrate content versus outcome median blood glucose. In Figure 11, both 
groups had zero feed rates at some portions for very short staying patients. In 
SPRINT, some patients were not fed, which corresponds to ~1-2% of hours with no 
feed rate as shown in Figure 4. Overall, these plots show the metabolic balance 
achieved for each patient between insulin and carbohydrate inputs and the resulting 
glycemic outcome. They also clearly show the outlying patients with unbalanced 
and/or extreme insulin and nutrition inputs resulting in poor(er) glycemic control to 
the desired target. 
 
While this study does not directly examine mortality outcomes, the range of 
carbohydrate administration between all of Glucontrol and SPRINT was examined. 
Median carbohydrate administration rate (per-patient) was not associated with 
mortality in SPRINT (p = 0.82). However, there was a strong association with 
mortality in the overall Glucontrol cohort (p = 0.03).  
 
Finally, Figure 14 illustrates the inter-patient variability in the resulting glycemic 
outcome(s). The per-patient CDFs shown reveal a tighter result across patients, 
particularly over the 25th to 75th percentile inter-quartile range patients, for the 
SPRINT protocol despite the differences or variability noted in prior results. The 
same lower variability seen for SPRINT over the cohort (steeper CDF in Figure 2) is 
also evident for all percentile patients in Figure 14, in comparison to the Glucontrol 
cohorts shown in Figure 14. 
 
4.0 Discussion 
 
SPRINT achieved tighter control than Glucontrol A or B (for the one centre 
examined) around their respective target glycemic levels, as clearly seen in Figure 5. 
The steeper CDFs indicate the lower, by cohort, glycemic variability. Importantly, the 
Glucontrol CDFs are very similar, but (primarily) shifted to their respective target 
glucose levels, resulting in higher hypoglycemia for the Group A cohort with the 
lower target. This result is reinforced by the steeper and less variable per-patient 
CDFs for the middle 50% of patients (IQR) in each cohort shown in Figures 14, 
which thus indicates the ability of each protocol to manage inter-patient variability.  
 
The higher incidence of hypoglycemia for lower percentile patients is clearer in 
Figure 14. In particular, it indicates that the intensive Glucontrol A protocol could not 
effectively account for the inter- and intra- patient variability in metabolic behaviour 
seen in Figures 5-8, despite the wider range of (median) insulin and nutrition inputs 
used, as shown in Figures 10-13. Hence, some Glucontrol-A patients were simply 
controlled by the protocol to too low of a glycemic level, resulting in increased risk of 
hypoglycemia, which has been commonly reported in other studies (e.g. [19, 22, 46]). 
 
This outcome clearly indicates that the Group A Glucontrol protocol was not able to 
fully account for differences between patients or/and intra-patient variability. This 
outcome was reinforced by the cohort and per patient results in Table 3, which show 
cohort IQR ranges for glycemic outcomes are much wider in this group than in the 
similarly targeted SPRINT case. As a result, SPRINT also had far less hypoglycemia. 
In terms of providing nutrition and insulin, SPRINT has a higher proportion of 
patients receiving, on average, more insulin than Group A, and more consistently as 
well for Group B (less zero values on the CDF in Figure 3). In current thinking [22, 
46-48], this increased insulin usage should have resulted in similar or greater 
hypoglycemia, which was not the case here.  However, SPRINT patients also received 
a more consistent input of carbohydrate administration from all sources compared to 
Glucontrol Groups A and B, as seen in the relatively very steep CDFs for SPRINT in 
Figure 4 with virtually no zero values. Considering the carbohydrate intake, noted that 
all sources of carbohydrate includes enteral and parenteral nutrition an iv dextrose. 
This difference in CDFs is critical given that the median and average values are 
similar across all 3 cohorts. However, per-patient results for all 3 cohorts show that 
the spread of carbohydrate administration rates was much tighter for SPRINT than for 
either Group A or Group B by a factor of almost 4x for median rates across patients, 
as seen in Table 2.  
 
Importantly, while Figure 11 shows that some SPRINT patients did have median zero 
feed rates, the work of Krishnan et al [26] shows that 33-66% of the ACCP guidelines 
is a more optimal rate of carbohydrate administration with respect to mortality 
outcome. The SPRINT data are thus clustered almost entirely in this range in Figure 
4. In contrast, the greater spread in Glucontrol data is due to not controlling this 
variable and local clinical practice for that patient cohort. Hence, it may not be 
unexpected that there was no correlation between mortality and median per-patient 
carbohydrate administration in SPRINT, but that it was significant considering all 
Glucontrol patients. 
 
These results indicate that the higher insulin usage combined with consistent, tightly 
managed carbohydrate input was balanced in the SPRINT protocol resulting in less 
glycemic variation and, for similar target glucose, less hypoglycemia. More 
specifically, the SPRINT protocol interventions were both more consistent and, within 
their tighter range, better able to manage the inter- and intra- patient variation in their 
cohort. Overall, hypoglycemia and tight control are, as might be expected, explicit 
functions of the nutrition and insulin dosing, leading to the conclusion that explicit 
knowledge of carbohydrate intake must be accounted for (if not explicitly controlled) 
in successful TGC, which is a result reported in independent studies [49]. In 
particular, without this information, it will be far more difficult to strike a safe, long-
term and consistently achieved glycemic balance. 
 
Thus, variability and/or inconsistency in insulin and nutritional carbohydrate inputs 
are one source of glycemic variability. A second major source would be the metabolic 
inter- and intra- patient variability, all else equal, of the cohort, where a more variable 
cohort would potentially be expected to have a more variable glycemic outcome. 
Figures 5-6 clearly shows that the Glucontrol cohorts span a wider range of insulin 
sensitivity than the SPRINT cohort with more inter-patient variability. However, their 
hour-to-hour variation can significantly affect the level of glycemic control, especially 
in cases with less frequent measurement where small evolutions over several hours 
can result in large changes in metabolic status and glycemic outcome for a constant 
infusion of insulin and nutrition. Hourly changes are the same for both Glucontrol and 
SPRINT given the similar plots in Figure 9 where 1 hour variations may be 
considered significant with respect to glycemic control and interventions when 
outside a 15% change from the prior hour [38, 50]. However, interestingly, Figures 7-
9 show very similar results between the cohorts for this intra-patient variability. Note 
that, while not shown, recreating Figure 9 separating Groups A and B yields the same 
result. Hence, while insulin sensitivity distributions were different between the 
SPRINT and Glucontrol cohorts, their hour-to-hour variability is very similar, which 
is an unexpected result and indicates a more universal behaviour may be evident. 
 
Two conclusions may be drawn from this result. First, any protocol must be able to 
adapt to a given patient’s specific level of insulin resistance and its changes over time, 
thus accounting for inter- and intra- patient variability. It is clear that Glucontrol was 
potentially unable to manage one or both of these aspects, as per-patient glycemic 
outcomes in Figure 14 were similar shaped (in CDF) across Group A and Group B 
with a simple shift due to the different glycemic targets. Second, to better control 
glycemic levels carbohydrate administration must be explicitly accounted for in the 
protocol design and implementation, which enables assessment or estimation of 
effective insulin sensitivity in real-time in response to interventions. In particular, this 
data would allow protocols to adapt their inputs to match gradual or acute changes in 
a patient’s metabolic status (insulin resistance or insulin sensitivity SI), which is what 
SPRINT effectively does [13, 24], and thus to provide potentially tighter control and 
more consistent care. 
 
This last point may be critical when considering Glucontrol and other multi-centre 
trials. Glucontrol, NICE-SUGAR and VISEP [20, 29, 51] were all multi-centre trials 
that reported increased hypoglycemia with tighter/lower glycemic target groups, as 
well as failing to show benefit from TGC. In these recent studies, nutritional inputs 
were (largely) left to local standards of care, which can be quite variable both between 
centres and between clinicians in a centre. As seen in these results, the level of 
hypoglycemia for Glucontrol Group A at CHU of Liege was still lower than the ~12% 
by patient level that stopped the multi-centre VISEP trial. Thus, it might be concluded 
that the variation of nutrition across centres in that trial resulted in even further 
variation in glycemic outcome for the fixed insulin delivery protocols used (all else 
equal). Hence, the result for the intensively controlled Group A would have been even 
further hypoglycemia and even more variable control around the target level when run 
over multiple centres, as was indeed the case in the final multi-centre report [29]  with 
8.7% of patients experiencing hypoglycemia for Group A versus 7.7% in the insulin 
treated Group A cohort examined here from the single Glucontrol pilot study centre. 
Certainly, this variability in nutrition input (alone) is evident in Figure 11 where 
median input rates span a very wide range. In contrast, explicit protocol knowledge of 
carbohydrate administration has, in both cases it has been used [13, 23], resulted in 
tighter control with minimal hypoglycemia. 
 
One potential limitation of this study is that it uses a model-based metric of insulin 
sensitivity (SI) to assess inter- and intra- patient variability. Thus, it should be noted 
that all cohorts studied here have measurable numbers of patients with diagnosed 
and/or undiagnosed type 2 diabetes mellitus (T2DM). However, the difference in 
insulin resistance between T2DM individuals and otherwise normal individuals are 
small in hyperglycemic critical care patients. In particular, non-critically ill T2DM 
individuals have an insulin sensitivity of SI = 1.0-2.0e-3 (L/mU/min) in insulin 
sensitivity tests using this model [44, 45]. This range of values covers only a very few 
patients or hours in Figures 5-7 for the least resistant (most sensitive). The typical 
critically ill patient, with or without T2DM, has a significantly counter-regulated 
metabolic system that drives effective insulin resistance, as measured by this 
clinically validated model, to values well below an otherwise healthy T2DM 
individual. Thus, there is little impact expected on the overall glycemic outcomes and 
this analysis due to a subset of patients with this diagnosis. In SPRINT in particular, 
there were no differences in glycemic or mortality outcome for diabetic individuals. 
 
Finally, it should be noted that the Glucontrol data examined here was only from one 
centre (CHU de Liege, Belgium) where the protocol was piloted. While the glycemic 
outcomes of the two protocols in this subset are similar to those over the study, it 
should be noted that these results could potentially differ if the full 21 centre study 
data set were considered. However, the overall goal of this article was to examine 
differences in glycemic control outcomes and the associated control inputs to define 
aspects that can result in greater success or difficulty in obtaining tight glycemic 
control. In that context, the study presented is valid, and a further analysis using the 
full data set, when available, might better define these results as well as characterise 
where variability across centres, within a given protocol, had positive and negative 
effects on TGC. 
 
More importantly, from this study, it can be evaluated that clear guidelines for 
nutrition intake of carbohydrate are essential in TGC protocol regardless of the 
nutritional standards and practises across different countries. In addition, considering 
frequent and convenient measurement, future protocols should also consider bedside 
glucose monitoring systems for reduced clinical effort and better control. For future 
studies, comparison of protocols that achieve high level of compliance should be 
evaluated. 
 5.0 Conclusions 
 
Three main conclusions may be drawn from this analysis: 
 
1. Successful TGC protocols must be able to account for the significant inter- 
and intra- patient variability in insulin resistance (sensitivity) that can be 
observed in critically ill cohorts. 
 
2. a) Explicit knowledge of, and potentially control of, carbohydrate 
administration within reasonable limits reported in the literature, 
appears to be a mandatory component in reducing outcome glycemic 
variability and thus, potentially, in achieving all of the benefits of TGC 
with minimal risk. It is a factor that is missing from many of the 
published protocols to date. 
 
b) Limits to non-saturable ranges of insulin infusion or intervention of 0-8 
U/hour would also limit the changes seen in glycemia when intra-
patient variability is high. 
 
3. While inter-patient variability in insulin sensitivity can be quite different 
between cohorts that are otherwise similar in severity of illness, the evolution 
and dynamic change or intra-patient variability of this parameter appears to be 
very similar across (at least) the cohorts studied here. 
 
All of these main conclusions remain to be prospectively tested. However, this 
analysis highlights key aspects of TGC trials and data that can be used in developing 
improved protocols, as well as used for retrospective analysis and comparisons that 
may have been previously overlooked.  
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Table 3: Comparison of Glucontrol and SPRINT cohorts. The p-values are for 
comparing the Glucontrol A+B cohorts together versus SPRINT 
 
 SPRINT Glucontrol P value 
A B 
Number of patients 393 142 69  
Percentage of males (%) 62.8 64.8 56.5 0.8531 
Age [IQR] 65 [50 – 74] 71 [61 – 80] 69 [53 – 77] 0.0011 
Apache II score median 
[IQR] 
 
18 [14 – 24] 
 
17 [14 – 22] 
 
17 [14 – 21] 
 
0.3894 
Hours of control 49,008 16831 12946  
Total BG measurement 29,919 4571 2820  
 
Cohorts 
BG median [IQR] (mmol/L)  
5.7 [5.0 – 6.6] 
 
6.3 [5.3 – 7.6] 
 
8.2 [6.9 – 9.4] 
 
Insulin rate median [IQR] 
(mU/min)  
 
50.0 [16.7 – 50.0] 
 
25.0 [8.3 – 50.0] 
 
11.7 [0.0 – 28.3] 
 
Feed rate of carbohydrate 
median [IQR] (mmol/min)  
 
0.42 [0.25 – 0.52] 
 
0.30 [0.00 – 0.90] 
 
0.60 [0.10 – 1.00] 
 
No. of patient with BG less 
than 2.2 mmol/L 
 
8 (2.0%) 
 
11 (7.7%) 
 
2 (2.9%) 
 
Percentage of measurement 
less than 2.2 mmol/L (%) 
 
0.05 
 
0.4 
 
0.1 
 
Percentage of measurement 
less than 3.0 mmol/L  (%) 
 
0.28 
 
1.3 
 
0.4 
 
Percentage of measurement 
less than 4.0 mmol/L  (%) 
 
3.9 
 
5.3 
 
0.8 
 
Percentage of measurement 
less than 4.4 mmol/L  (%) 
 
9.4 
 
9.4 
 
1.7 
 
Percentage of measurement 
between 4.4 and 6.1 mmol/L  
(%) 
 
48.2 
 
35.8 
 
10.4 
 
Percentage of measurement 
between 7.8 and 10.0 mmol/L  
(%) 
 
6.2 
 
15.6 
 
40.6 
 
Percentage of measurement 
greater than 8.0 mmol/L  (%) 
 
8.0 
 
20.3 
 
52.5 
 
 
 
 
Per Patient Results 
Hours of control  
median [IQR] 
 
53 [19 – 149] 
 
61 [38 – 138] 
 
89 [43 – 229] 
 
Number of BG measurements 
taken: median [IQR] 
 
37 [16 – 97] 
 
19 [11 – 37] 
 
22 [11 – 47] 
 
BG median [IQR] (mmol/L)  
5.8 [5.3 – 6.4] 
 
6.4 [5.9 – 6.9] 
 
8.3 [7.6 – 8.8] 
 
 
Insulin rate median [IQR] 
(mU/min) 
 
50.0 [33.3 – 50.0] 
 
25.0 [13.3 – 33.3] 
 
8.3 [0.0 – 16.7] 
 
 
Feed rate median [IQR] 
(mmol/min) 
0.37 [0.20 – 0.48] 0.1 [0.0 – 0.8] 0.2 [0.0 – 0.7]  
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Figure 2: CDF of measured blood glucose on cohort basis for SPRINT, Group A and 
Group B (Glucontrol). 
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Figure 3: CDF for hourly insulin infusion rate on cohort basis for SPRINT, Group A 
and Group B (Glucontrol). 
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Figure 4: CDF of nutrition rate on cohort basis for SPRINT, Group A and Group B 
(Glucontrol). 
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Figure 5: Empirical cumulative 
distribution functions per patient of insulin 
sensitivity on SPRINT. 
 
 
Figure 6: Empirical cumulative 
distribution    functions per patient of 
insulin sensitivity on Glucontrol. 
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Figure 7: Fitted hourly SI variation and 
probability distribution function of 
Glucontrol (1-2 hours interval). 
 
Figure 8: Fitted hourly SI variation 
and probability distribution 
function of SPRINT. 
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Figure 9: Fitted hourly SI variation and probability distribution function of SPRINT and 
Glucontrol with 1-2 hours measurement interval. The trends are very similar at most SI 
values with differences at very low insulin sensitivity (SI) due to lower numbers of data 
points in the Glucontrol cohort, per Figures 5-6. 
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Figure 10: Three dimensional plot of median insulin rate, median feed rates and median 
BG for SPRINT and Glucontrol (Group A and Group B).  
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Figure 11: Distribution of median feed rates (all sources) versus median blood glucose 
measured for SPRINT and Glucontrol (Group A and Group B). 
2 4 6 8 10 12 14 16
0
20
40
60
80
100
120
140
median BG (mmol/L)
m
ed
ia
n 
In
su
lin
 (
m
U
/m
in
)
 
 
SPRINT
Group A
Group B
 
Figure 12: Distribution of median insulin versus median blood glucose measured for 
SPRINT and Glucontrol (Group A and Group B). 
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Figure 13: Distribution of median insulin against median feed rates (all sources) for 
SPRINT and Glucontrol (Group A and Group B). 
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Figure 14: Empirical cumulative distribution functions per patient of measured blood 
glucose on: a) Group A of Glucontrol, b) Group B of Glucontrol and c) SPRINT. Lines 
show the 5th, 25th, 50th (median), 75th and 95th percentile patient responses and shaded 
areas show the resulting inter-quartile and 90% CI ranges. All x and y axes have the same 
scale. 
 
